{"filing":{"accession_number":"0001213900-26-102611","cik":"0001721484","ticker":"LGVN","company_name":"Longeveron Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-16","primary_document":"ea0306147-8k_longeveron.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/ea0306147-8k_longeveron.htm"},"events":[{"id":34567,"run_id":31812,"accession_number":"0001213900-26-102611","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Longeveron announced that its Phase 2b ELPIS II clinical trial did not meet its primary efficacy endpoint for laromestrocel in treating hypoplastic left heart syndrome, a material clinical development setback for a clinical-stage biotech company. Additionally, the company announced it is reviewing \"all options to maximize shareholder value\" and implementing \"cash conservation measures,\" signaling potential strategic restructuring or asset sales. This is a material operational and strategic event—the failure of a pivotal trial combined with a strategic review process—but does not fit neatly into specific categories like ma_activity (no transaction announced yet) or material_impairment (no accounting charge disclosed). The operational domain is clear; the specific type is a clinical trial failure with strategic implications.","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38323,"accession_number":"0001213900-26-102611","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Longeveron announced that its Phase 2b ELPIS II clinical trial did not meet its primary efficacy endpoint for laromestrocel in treating hypoplastic left heart syndrome, a material clinical development setback for a clinical-stage biotech company. Additionally, the company announced it is reviewing \"all options to maximize shareholder value\" and implementing \"cash conservation measures,\" signaling potential strategic restructuring or asset sales. This is a material operational and strategic event—the failure of a pivotal trial combined with a strategic review process—but does not fit neatly into specific categories like ma_activity (no transaction announced yet) or material_impairment (no accounting charge disclosed). The operational domain is clear; the specific type is a clinical trial failure with strategic implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:03:16.184107+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38323,"accession_number":"0001213900-26-102611","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Longeveron announced that its Phase 2b ELPIS II clinical trial did not meet its primary efficacy endpoint for laromestrocel in treating hypoplastic left heart syndrome, a material clinical development setback for a clinical-stage biotech company. Additionally, the company announced it is reviewing \"all options to maximize shareholder value\" and implementing \"cash conservation measures,\" signaling potential strategic restructuring or asset sales. This is a material operational and strategic event—the failure of a pivotal trial combined with a strategic review process—but does not fit neatly into specific categories like ma_activity (no transaction announced yet) or material_impairment (no accounting charge disclosed). The operational domain is clear; the specific type is a clinical trial failure with strategic implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:03:16.184107+00:00","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-09-23"}]}